Cargando…
Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lym...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679379/ https://www.ncbi.nlm.nih.gov/pubmed/26722358 http://dx.doi.org/10.7150/jca.13090 |
_version_ | 1782405571007217664 |
---|---|
author | Wu, San-Gang He, Zhen-Yu Ren, Hong-Yue Yang, Li-Chao Sun, Jia-Yuan Li, Feng-Yan Guo, Ling Lin, Huan-Xin |
author_facet | Wu, San-Gang He, Zhen-Yu Ren, Hong-Yue Yang, Li-Chao Sun, Jia-Yuan Li, Feng-Yan Guo, Ling Lin, Huan-Xin |
author_sort | Wu, San-Gang |
collection | PubMed |
description | Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lymph node metastasis (ALNM) in patients with breast cancer. Methods: This retrospective study analyzed 1148 breast cancer patients whose preoperative CEA and CA 15-3 levels were measured. The association of these tumor markers and clinicopathologic parameters with ALNM was determined by univariate and multivariate analysis. Results: A median of 15 lymph nodes were removed. Seven hundred seventy-eight (67.8%) patients had node-negative disease and 370 (32.2%) had ALNM. Univariate analysis showed that tumor location (P = 0.024), stage (P = 0.001), grade (P < 0.001), lymphovascular invasion (LVI) (P < 0.001), CEA level (P < 0.001), CA15-3 level (P < 0.001), and breast cancer subtype (BCS) (P < 0.001) were significantly associated with ALNM. ALNM was present in 4.5% of patients with normal CEA and 11.6% of patients with elevated CEA. ALNM was present in 8.0% of patients with normal CA15-3 and 17.0% of patients with high CA15-3. Multivariate logistic regression analysis showed that tumor location, stage, grade, LVI, CEA, CA15-3, and BCS were significantly and independently associated with ALNM (P < 0.05 for all). Conclusion: The probability of ALNM was greater in patients with elevated preoperative serum levels of CEA and CA15-3. CEA and CA15-3 appear to be independent predictors of ALNM in breast cancer. |
format | Online Article Text |
id | pubmed-4679379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-46793792016-01-01 Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer Wu, San-Gang He, Zhen-Yu Ren, Hong-Yue Yang, Li-Chao Sun, Jia-Yuan Li, Feng-Yan Guo, Ling Lin, Huan-Xin J Cancer Research Paper Purpose: The clinical significance of preoperative serum levels of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in breast cancer is controversial. The purpose of this study was to assess the clinical value of preoperative serum levels of CEA and CA 15-3 on the risk of axillary lymph node metastasis (ALNM) in patients with breast cancer. Methods: This retrospective study analyzed 1148 breast cancer patients whose preoperative CEA and CA 15-3 levels were measured. The association of these tumor markers and clinicopathologic parameters with ALNM was determined by univariate and multivariate analysis. Results: A median of 15 lymph nodes were removed. Seven hundred seventy-eight (67.8%) patients had node-negative disease and 370 (32.2%) had ALNM. Univariate analysis showed that tumor location (P = 0.024), stage (P = 0.001), grade (P < 0.001), lymphovascular invasion (LVI) (P < 0.001), CEA level (P < 0.001), CA15-3 level (P < 0.001), and breast cancer subtype (BCS) (P < 0.001) were significantly associated with ALNM. ALNM was present in 4.5% of patients with normal CEA and 11.6% of patients with elevated CEA. ALNM was present in 8.0% of patients with normal CA15-3 and 17.0% of patients with high CA15-3. Multivariate logistic regression analysis showed that tumor location, stage, grade, LVI, CEA, CA15-3, and BCS were significantly and independently associated with ALNM (P < 0.05 for all). Conclusion: The probability of ALNM was greater in patients with elevated preoperative serum levels of CEA and CA15-3. CEA and CA15-3 appear to be independent predictors of ALNM in breast cancer. Ivyspring International Publisher 2016-01-01 /pmc/articles/PMC4679379/ /pubmed/26722358 http://dx.doi.org/10.7150/jca.13090 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Wu, San-Gang He, Zhen-Yu Ren, Hong-Yue Yang, Li-Chao Sun, Jia-Yuan Li, Feng-Yan Guo, Ling Lin, Huan-Xin Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title | Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title_full | Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title_fullStr | Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title_full_unstemmed | Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title_short | Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer |
title_sort | use of cea and ca15-3 to predict axillary lymph node metastasis in patients with breast cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679379/ https://www.ncbi.nlm.nih.gov/pubmed/26722358 http://dx.doi.org/10.7150/jca.13090 |
work_keys_str_mv | AT wusangang useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT hezhenyu useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT renhongyue useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT yanglichao useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT sunjiayuan useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT lifengyan useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT guoling useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer AT linhuanxin useofceaandca153topredictaxillarylymphnodemetastasisinpatientswithbreastcancer |